Skip to main content
. 2018 Nov 2;13(11):e0206542. doi: 10.1371/journal.pone.0206542

Fig 2.

Fig 2

(A) ROC curve analyses to evaluate the potential utility of miR-21, miR-99b, miR-375 and their combination to distinguish patients with maximum response to neoadjuvant treatment (TRG4) from others. (B) ROC curve analysis comparing the miRNA combination with pre-CRT clinical stage and CEA levels.